Survival after the diagnosis of breast or colorectal cancer in the GAZA Strip from 2005 to 2014

Survival after the diagnosis of breast or colorectal cancer in the GAZA Strip from 2005 to 2014 Background: Within a dramatic socio-political context, cancer represents a growing health burden in the Gaza Strip. We investigated the survival experience of people diagnosed with breast (BC) or colorectal (CRC) cancer from 2005 to 2014. Methods: Data included 1360 BC cases (median age 55.1 years) and 722 CRC cases (median age: 59.5 years; 52.5% men) recorded by the Gaza Cancer Registry according to a standard protocol. Clinical information was available for cases diagnosed in 2005–2006 only. Survival probabilities were estimated by Kaplan-Meyer method, while hazard ratios (HRs) and 95% confidence intervals (CI), adjusted for age and sex, were computed to assess factors associated with the risk of death. Results: Five-year survival was 65.1% for women with BC and 50.2% for patients with CRC. Advanced age (> 65 years), stage, and grade increased the death risk. Full access to therapies was associated with a reduced risk of death as compared with patients who had limited access (HR = 0.26, 95% CI:0.13–0.51 for BC; and HR = 0.11, 95% CI: 0.04–0.31 for CRC). Conclusion(s): The 5-year survival after BC or CRC in the Gaza Strip was in line with estimates from surrounding Arab countries, but it was much lower than in developed Mediterranean countries (e.g., in Italy or in Jewish people in Israel). Keywords: Gaza Strip, Cancer survival, Breast cancer, Colorectal cancer Background of death, after cardiovascular diseases, and it accounts The Gaza Strip, a narrow land located in the southern for 20% of the whole expenditure for drugs [5, 6]. part of the Occupied Palestinian Territory (OPT), is an In the OPT, two population-based cancer registries overcrowded area with a population of 1.8 million were established in 1996 by the Palestinian Ministry of people (i.e., 5000 persons per km )[1]. Although most Health (MoH) -one in the West Bank, and one in the of the population in the Gaza Strip has a challengeable Gaza Strip [4]. Given the geopolitical context of the life, with a high rate of poverty - 74% of families were es- Gaza Strip [7, 8], the data collection process cannot fully timated to live below the poverty line [2, 3] - life expect- reflect the whole cancer burden in the area. As a conse- ancy at birth reaches 71.5 years in males and 74.4 years quence, the World Health Organization (WHO) has re- in females [4]. Cancer is the second most common cause cently given support to the Palestinian MoH in improving cancer registration [8]. Of all cases recorded between 2005 and 2014, breast cancer (BC) was the most common cancer among women (26.0% -skin can- * Correspondence: serrainod@cro.it Chiara Panato and Khaled Abusamaan contributed equally to this work. cers included), while colorectal cancer (CRC) was the Cancer Epidemiology Unit, IRCCS Centro di Riferimento Oncologico, Aviano, second most common cancer in men (9.7% of all cases). Italy The Italian MoH promoted the “EUROMED Cancer Friuli Venezia Giulia Cancer Registry, IRCCS Centro di Riferimento Oncologico, Aviano, Italy Network” with the general aim to support extra-European Full list of author information is available at the end of the article © The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. Panato et al. BMC Cancer (2018) 18:632 Page 2 of 10 Union Mediterranean countries in the development of ef- for these cases a multivariate analysis was conducted to fective anti-cancer programs [9, 10]. The ongoing collab- estimate the risk of death. oration with the Gaza Cancer Registry (GCR) was conducted by the National Cancer Institute “Centro di Statistical methods Riferimento Oncologico”, Aviano (notheastern Italy); the The crude survival time was calculated as the time Italian network of cancer registries (AIRTUM); and the elapsed from date of cancer diagnosis to date of death, Italian National Health Institute (ISS), Rome. or to end of follow-up –whichever came first. At univar- Herein, we describe the general characteristics and the iate analysis, the survival time for the totality of BC or crude survival experience of patients diagnosed with BC CRC patients diagnosed from 2005 to 2014 was esti- or with CRC between 2005 and 2014 in the Gaza Strip. mated by means of the Kaplan-Meier method [11]. Furthermore, as selected clinical data were available only For cases diagnosed in 2005–2006 only, a multivariate for cases diagnosed in 2005–2006, we estimated the risks analysis was carried out to statistically assess the role of of death for patients with BC or CRC according to type selected clinical variables on survival. To this end, haz- of therapy, disease, grade, or stage. ard ratios (HRs) for all-cause mortality, and the corre- sponding 95% confidence intervals (95% CIs), were estimated using the Cox proportional hazard model ad- Methods justed for age at diagnosis (< 35, 35–44, 45–54, 55–64, Study population 65–74, 75+ years) and gender, as appropriate [12]. The We described the general characteristics and the cancer proportional hazard assumption was assessed through survival experience of people living in the Gaza Strip, di- Schoenfeld residuals, including interactions with agnosed with BC or CRC in 2005–2014, according to follow-up time [12]. the information recorded in the population-based GCR. Cancer Registries are identified as collectors of personal Results data for surveillance purposes without the need of expli- Breast cancer cit individual consent. The approval of a research ethic The median age of the 1360 women diagnosed with BC committee is not required because neither direct nor in- in the Gaza Strip between 2005 and 2014 was 55.1 years direct intervention on patients took place. Nonetheless, (Inter Quartile Range -IQR: 45.8–64.8 years). The abso- the General Director of the Primary Health Care, MoH, lute number of cases more than doubled, from 178 in (Dr. Fouad Elissawi) cleared the use of the registry data 2005–2006 up to 396 in 2013–2014 (Table 1), with slight for study purposes. The data collection process used by variations in median ages –from 53.0 years (in 2005– GCR is an active one, carried on by GCR trained 2006) to 55.4 years (in 2013–2014). Overall, 76.1% (95% personnel who regularly visit the pathology departments and oncology clinics to collect newly detected cases and Table 1 Description of breast and colorectal cancer incident to update the already recorded ones. The update of the cases diagnosed from 2005 to 2014 in the Gaza Strip vital status is manually checked by means of the death Breast cancer Colorectal cancer registry. Cases Deaths Cases Deaths For the aims of this analysis, to ensure data validity, N = 1360 N = 486 (%) N = 722 N = 361 (%) each case was reviewed by a member of the GCR and Sex co-author of this article (FE). The vital status and – Female 1360 486 (35.7) 343 169 (49.3) eventually – the date of death were ascertained from the Male –– 379 192 (50.7) death registration database at Palestinian MoH. The last follow-up time was December 31st, 2016. Overall, from Age at cancer diagnosis (years) 2005 to 2014, 1495 women were diagnosed with BC (no ≤ 44 331 108 (32.6) 97 33 (32.0) cases of BC were recorded in men during the study 45–54 371 120 (32.4) 163 69 (40.5) period), and 878 people were diagnosed with CRC. This 55–64 319 112 (35.1) 221 114 (49.3) analysis was restricted to 1360 BC and 722 CRC patients ≥ 65 339 146 (43.1) 241 145 (59.3) after exclusion of: cases lacking the full date of birth (7 Calendar year at cancer diagnosis BCs and 21 CRCs); children under 15 years of age (2 BCs and 3 CRCs); and those patients with coincident 2005–2006 178 93 (52.3) 80 58 (72.5) dates of diagnosis and death (126 cases of BC and 132 2007–2008 207 73 (35.3) 124 53 (47.7) cases of CRC). 2009–2010 223 101 (45.3) 136 72 (52.9) Information on therapy, grade, and stage of disease 2011–2012 356 143 (40.2) 165 91 (55.2) was available for cases diagnosed in 2005–2006 only 2013–2014 396 76 (19.2) 217 87 (40.1) (i.e., 178 cases of BC and 80 cases of CRC). Accordingly, Panato et al. BMC Cancer (2018) 18:632 Page 3 of 10 CI: 73.7–78.3) of these women was alive after 3 years, disease were statistically lower than those with a local- 65.1% (95% CI: 62.1–67.4) after 5 years, and 51.9% (95% ized BC stage (p of log-rank test = 0.0314) (Fig. 2b). Con- CI: 47.9–55.7) after 10 years from BC diagnosis (Fig. 1a). cerning HR, advanced stage of disease was associated The probability of survival after BC was strongly influ- with an elevated risk of death as compared with those enced by age, with women aged 65 years or older show- with a localized disease – of borderline statistical signifi- ing the lowest survival rates (i.e., 66.0% after 3, 57.4% cance – (HR = 1.93, 95% CI: 0.98–3.80). Likewise, the after 5, and 45.1% after 10 years from diagnosis) (p < survival probabilities stratified by grade of disease were 0.001) (Fig. 1b). different from each other (p-value = 0.0078) (Fig. 2c), Selected clinical data available for the 178 women with and women diagnosed with poorly or undifferentiated BC diagnosed in 2005–2006 are discussed in detail BC were at 1.67-fold higher risk of death than women (Table 2). The majority of them (60.1%) was diagnosed with well/moderate grade of cancer (HR:1.67, 95% with an advanced stage of disease, but no difference was CI:1.04–2.69) (Table 2). noted between the percentage of women diagnosed with Surgically treated women (87.6%) had the best progno- well or moderately differentiated BC and those diag- sis, and those treated with two or more anti-cancer ther- nosed with a poorly differentiated or undifferentiated apies presented a statistically significant 70% reduction disease. Among these 178 patients with BC, 83.7% in the risk of death, as compared with those who had lit- underwent two or more therapies, in particular surgery tle (i.e., only one type of treatment) or no access (2.9%) (87.6%) and chemotherapy (76,4%). to anti-cancer therapies (Table 2). The 178 women diagnosed with BC between 2005 and 2006 were followed-up to December 31st, 2016 for a Colorectal cancer median period of 63.3 months (IQR: 23.0–100.3 months). The median age of the 722 individuals (47·5% women) During such period, 93 of them (52.2%) died, and 85 diagnosed with CRC in the Gaza Strip between 2005 and were censored. The estimated median survival time was 2014 was 59.5 years (IQR: 51.2–68.6 years), and the ab- 83.7 months (95% CI: 61.3–106.9) (Fig. 2a). Grade and solute number of cases ranged from 80 in 2005–2006 to stage of disease influenced the prognosis. Indeed, the 217 in 2013–2014 (Table 1). The median ages at CRC survival probabilities of women with advanced stage of diagnoses remained stable over time (58.7 years in Fig. 1 Kaplan-Meier estimates of survival probabilities among cases 1360 women diagnosed with breast cancer: overall (a) and according to age class (b). Gaza Strip, 2005–2014 Panato et al. BMC Cancer (2018) 18:632 Page 4 of 10 Table 2 Hazard ratios (HR) of all-cause deaths, with corresponding 95% confidence intervals (CI), among 178 incident breast cancer cases diagnosed in 2005–2006 in the Gaza Strip according to clinical characteristics Cases Deaths (N = 93) N N (%) HR (95% CI) Age at diagnosis (years) < 55 98 47 (48.0) 1 ≥ 55 80 46 (57.5) 1.39 (0.93–2.09) Stage Localized 33 10 (30.3) 1 Regional/Distant 107 57 (53.3) 1.93 (0.98–3.80) Missing 38 26 (68.4) 2.32 (1.10–4.91) Grade Well and Moderately differentiated 75 31 (41.3) 1 Poorly differentiated and Undifferentiated 70 42 (60.0) 1.67 (1.04–2.69) Missing 33 20 (60.6) 1.33 (0.72–2.44) Surgery No 18 14 (77.8) 1 Yes 156 76 (48.7) 0.29 (0.16–0.53) Chemotherapy No 38 23 (60.5) 1 Yes 136 67 (49.3) 0.58 (0.36–0.94) Radiotherapy No 81 46 (56.8) 1 Yes 93 44 (47.3) 0.89 (0·57–1·39) Hormone therapy No 109 63 (57.8) 1 Yes 65 27 (41.5) 0.53 (0.33–0.84) Number of therapies 0–1 25 20 (80.0) 1 2 55 29 (52.7) 0.32 (0.18–0.58) 3 56 23 (41.1) 0.25 (0.13–0.48) 4 38 18 (47.4) 0.26 (0.13–0.51) a b c Estimated using the Cox proportional hazard model adjusted for age; Reference category; The sum does not add up to the total because of missing values 2005–2006, 59.9 years in 2013–2014). Overall, 59.8% As per clinical protocols, 88.8% of these 80 cases diag- (95% CI: 56.0–63.3) of them were alive after 3 years, nosed in 2005–2006 underwent surgery, 87.5% received 50.2% (95% CI: 46.3–54.0) after 5 years, and 40.7% (95% chemotherapy, and only 27.5% radiotherapy. More than CI: 35.6–45.8) after 10 years from diagnosis (Fig. 3a). three quarters of patients underwent two or more thera- The survival probabilities after a CRC diagnosis were peutic regimens (Table 3). not influenced by sex (Fig. 3b). Conversely, survival after Figure 4a shows the overall survival of patients with CRC diagnosis was strongly influenced by age, with pa- CRC diagnoses, the median survival time was tients aged 65 years or older showing the lowest survival 43.3 months (95% CI: 31.4–60.0), and 34 patients were rates (i.e., 49.0% after 3, 40.1% after 5, and 33.8% after censored. Cases with a localized disease had a higher 10 years from diagnosis) (p < 0.001) (Fig. 3c). survival rate (i.e., 61.0% 5-years survival) than those with Women accounted for 60.0% of the 80 patients diag- regional/distant disease (i.e., 27.1% 5-years survival) nosed in 2005–2006 with a CRC (Table 3). Advanced (p-value = 0.0041) (Fig. 4b). Furthermore, CRC patients stage of disease was documented in 49 out of 80 patients with a regional/distant stage of disease had an elevated (61.3%), and a well or moderately differentiated grade of risk of death, as compared to those with a localized dis- cancer was documented in 53 out of 80 patients (66.3%). ease (HR = 3.38, 95% CI: 1.57–7.29) (Table 3). Similarly, Panato et al. BMC Cancer (2018) 18:632 Page 5 of 10 Fig. 2 Kaplan-Meier estimates of survival probabilities among 178 women diagnosed with breast cancer: overall (a); according to stage (b); and grade (c). The Gaza Strip, 2005–2006. The sum does not add up to the total because of missing values survival rates between patients with a well/moderate types of treatments), as compared with those who had grade of CRC (i.e., 53.9% 5-years survival) and those little (i.e., only one type of treatment) or no access (one with a poorly or undifferentiated grade (i.e., 13.6% patient) to anti-cancer therapies (Table 3). 5-years survival) were significantly different (p-value< 0.0001) (Fig. 4c). Likewise, CRC cases diagnosed with Discussion poorly or undifferentiated CRC were at 3.57-fold (95% Female BC and CRC are among the most common can- CI:1.87–6.81) higher risk of death than cases with well/ cers diagnosed every year worldwide in both more- and moderate grade of disease (Table 3). less-developed WHO regions [13]. These cancers are Patients who had been treated with two or more very common also in the Gaza Strip, where the present anti-cancer therapies presented a reduction in the risk of study attempted -for the first time- to estimate the sur- death (HR = 0.36 for those who received 2 out of three vival of people diagnosed with cancer in the Gaza Strip. modalities; HR = 0.11 for cases who underwent all 3 Our findings indicate that 65.1% of women with BC, and Panato et al. BMC Cancer (2018) 18:632 Page 6 of 10 Fig. 3 Kaplan-Meier estimates of survival probabilities among cases 722 cases diagnosed with colorectal cancer: overall (a), according to sex (b) and age class (c). Gaza Strip, 2005–2014 50.2% of patients with CRC were alive after 5 years the luminal B sub-type had a 5-year survival around from diagnosis. In the subgroup of patients with avail- 30%. A possible explanation of these results could be the able clinical information, the majority of patients were small sample size [16]. diagnosed at an advanced stage. Concerning survival after CRC, a study conducted in In agreement with our results, a Jordanian study dis- Israel among Bedouin Arab and Jewish patients with closed a five-year survival for BC patients of 59.3%, CRC is worth mentioning [17]. The five-year overall sur- showing that grade and stage had a significant effect on vival was about 65% in both ethnic groups. However, the survival rates [14]. Mean age at breast cancer diagnosis mean age at diagnosis was lower for the Bedouin Arab was similar in Jordan [14], in Egypt [15], and in the Gaza population (i.e., 57 years) than for the Jewish population Strip. The median survival time after BC in Egypt (i.e., (i.e., 69 years), pointing to a survival disadvantage for 83.8 months) was equal to the estimate in the Gaza Strip the Bedouin Arab ethnic group [17]. The 40% five-year (i.e., 83.7 months) [15] in 2005–2006. Furthermore, in survival for patients living in the Gaza Strip indicated a Uganda 5-year survival probability was between 50 and greater disadvantage in comparison with both Israeli 60% after a BC diagnosis, and in particular women with ethnic groups. Panato et al. BMC Cancer (2018) 18:632 Page 7 of 10 Table 3 Hazard ratios (HR) of all-cause deaths, with corresponding 95% confidence intervals (CI), among 80 cases of colorectal cancers diagnosed in 2005–2006 in the Gaza Strip according to clinical characteristics Cases Deaths (N = 46) N N (%) HR (95% CI) Age at diagnosis (years) < 60 44 23 (52.3) 1 ≥ 60 36 23 (63.9) 1.38 (0.77–2.48) Sex Male 32 20 (62.5) 1 Female 48 26 (54.2) 0.88 (0.48–1.59) Stage Localized 27 10 (37.0) 1 Regional/Distant 49 35 (71.4) 3.38 (1.57–7.29) Grade Well and moderately differentiated 53 23 (43.4) 1 Poorly differentiated and Undifferentiated 22 19 (86.4) 3.57 (1.87–6.81) Surgery No 9 9 (100.0) 1 Yes 71 37 (52.1) 0.27 (0.13–0.62) Chemotherapy No 10 8 (80.0) 1 Yes 70 38 (54.3) 0.37 (0.16–0.87) Radiotherapy No 58 38 (65.5) 1 Yes 22 8 (36.4) 0.24 (0.10–0.56) Number Therapies 0–1 18 16 (88.9) 1 2 40 22 (55.0) 0.36 (0.17–0.74) 3 22 8 (36.4) 0.11 (0.04–0.31) a b c Estimated using Cox proportional hazard model adjust for sex and age; Reference category; The sum does not add up to the total because of missing values The comparison of data from the GCR with those 71.1% in Izmir, Turkey, in women diagnosed from 1995 from highly-developed countries highlighted substantial to 1997 and followed-up to 2003, or to 61.3% in Saudi differences. In the Gaza Strip, the percentage of BC pa- Arabia, among women diagnosed in 1994–1996 and tients with localized disease at diagnosis was about half followed-up to 2001 [21]. Similar variations emerged, at than that recorded in most European countries, and population level for survival after CRC diagnosis, from a similar to the picture described in eastern European raw 5-year survival of nearly 23% in Setif to 52% in Izmir countries [18]. For CRC cases, the proportion of lo- [20]. calized diseases in the Gaza Strip was about two-fold Among the study strengths, the survival of cancer pa- higher than that documented by Italian cancer regis- tients living in the Gaza Strip was assessed at a popula- tries [19]. With respect to treatment, the proportion tion level, while other studies were previously conducted of patients in the Gaza Strip who underwent chemo- in clinical setting [22, 23]; moreover, we described the therapy and/or radiotherapy was higher than the propor- heterogeneity survival. On the other hand, accuracy and tion of Italian patients (88% vs. 39 and 28% vs. 10%, completeness of data collection, in this study, might respectively). have suffered of potential limitations. With regards to In contrast with widely available estimates of cancer the accuracy of information, the data from the GCR may incidence rates, survival estimates at population level in have suffered of limitations due to the socio-economic less developed countries -including the WHO EMR- are situation and to the conflicts in the Gaza Strip, which less common [20]. The 5-year raw survival after BC var- may have limited the activity of the health personnel ied substantially, from 38.8% in Setif (Algeria) [20]to working in the West Bank and in Gaza. Furthermore, Panato et al. BMC Cancer (2018) 18:632 Page 8 of 10 Fig. 4 Kaplan-Meier estimates of survival probabilities among 80 cases diagnosed with colorectal cancer: overall (a); according to stage (b); and grade (c). The Gaza Strip, 2005–2006. The sum does not add up to the total because of missing values because of cultural taboos (e.g., negative and false per- updated indications on the state of oncologic health care ception toward cancer patients with a consequent isola- in the Gaza Strip. Moreover, it tries to address the prob- tion from family members), cancer patients tend to lematic cancer care situation in this population. conceal their disease, which hinders their access to local The closure policy of the Gaza Strip for security rea- hospitals. Concerning completeness, although cancer sons has caused an isolation of Gaza citizens. This isola- registration in the Gaza Strip started in 1996, it still faces tion has affected the possibility to have adequate cancer several obstacles such as lack of appropriate hardware and care for many cancer patients living in the Gaza Strip. In software, insufficient staff, and training of health particular, the denial or delay of permits to travel outside personnel. All these concerns represent key issues in the Gaza Strip for cancer patients referred to its two neigh- accurate assessment of the cancer burden in the Gaza bouring countries (namely, Israel and Egypt) limits the Strip. opportunity of adequate diagnosis and/or treatment. Notwithstanding this lack of completeness, our study Moreover, a number of antineoplastic medications are results represent one of the first attempts to provide denied to patients due to the embargo [5, 24]. Panato et al. BMC Cancer (2018) 18:632 Page 9 of 10 Conclusions Friuli Venezia Giulia Cancer Registry, IRCCS Centro di Riferimento Oncologico, Aviano, Italy. In view of this already acknowledged difficult social, pol- itical, and economical context, the results from the Received: 3 October 2017 Accepted: 24 May 2018 present oncologic investigation further stresses the need to thoroughly re-assess and overcome the obstacles to a proper delivery of health care to the people living in the References Gaza Strip. It is the scope of the continuing collabor- 1. Palestinian Central Bureau of Statistics. Palestine in Figures 2015. Ramallah – Palestine. 2016. http://www.pcbs.gov.ps/Downloads/book2188.pdf (Last ation between Italian cancer registries and the GCR to access: 29 Aug 2017). contribute in supplying updated oncologic data from the 2. Giacaman R, Khatib R, Shabaneh L, Ramlawi A, Sabri B, Sabatinelli G, et al. Gaza Strip. Health status and health services in the occupied Palestinian territory. Lancet. 2009;373:837–49. Abbreviations 3. UNRWA. United Nations Relief and works agency: Gaza in 2020 a liveable BC: Breast cancer; CIs: Confidence intervals; CRC: Colorectal cancer; place? A report by the United Nations country team in the occupied EMR: Eastern Mediterranean region; GCR: Gaza Cancer Registry; HRs: Hazard Palestinian territory, August 2012. United Nations: Jerusalem. 2012. https:// ratios; IQR: Inter Quartile Range; MoH: Ministry of Health; OPT: Occupied www.unrwa.org/newsroom/press-releases/gaza-2020-liveable-place (last Palestinian Territory; WHO: World Health Organization access: 29 Aug 2017). 4. Ministry of Health. Health Status in Palestine-Ministry of Health Annual Acknowledgements report 2014. Palestine. 2015. http://www.moh.gov.ps/portal/Arabic version. The authors wish to thank Mrs. Luigina Mei for editorial assistance. (last access: 29 Aug 2017). 5. Husseini A, Abu-Rmeileh NM, Mikki N, Ramahi TM, Ghosh HA, Barghuthi N, Funding et al. Cardiovascular diseases, diabetes mellitus, and cancer in the occupied This work was supported by the Italian Ministry of Health – project title: Palestinian territory. Lancet. 2009;373:1041–9. “Sorveglianza epidemiologica per il controllo delle malattie neoplastiche nei 6. Ministry of Health. Palestinian Health Information Center (PHIC), Pharmaceutical paesi del Mediterraneo: dalla registrazione del cancro ai modelli statistici” situation in Gaza-2015. Palestine. 2016. http://www.moh.gov.ps/portal/wp- (Grant N.: I85J12000380005). content/uploads/2015 pharmacy (arabic). (Last access: 29 Aug 2017). Role of funding body: The funding body had no direct role in study design 7. American Cancer Society. Global Cancer Facts & Figures 2nd Edition. and data collection, in the data analysis and interpretation, as well as in the Atlanta, USA: American Cancer Society; 2011e. Available at: http:// manuscript writing. oralcancerfoundation.org/wp-content/uploads/2016/03/acspc-027766.pdf. 8. WHO. World Health Organization. occupied Palestinian territory (oPT). Availability of data and materials Situation report # 2, 27 December 2015; http://www.emro.who.int/pse/ The datasets used and/or analysed during the current study are available palestine-infocus/situation-reports.html (Last access: 29 Aug 2017). from the Gaza Cancer Registry (point of contact: MS Haia, 9. Giordano L, Bisanti L, Salamina G, Ancelle Park R, Sancho-Garnier H, haiayaghi@yahoo.com) upon reasonable request. Espinas J, et al. The EUROMED CANCER network: state-of-art of cancer screening programmes in non-EU Mediterranean countries. Eur J Pub Authors’ contributions Health. 2016;26:839. DS conceived and designed the study; CP, DS and KA drafted the article; MD 10. Hamdi Cherif M, Serraino D, Mahnane A, Laouamri S, Zaidi Z, Boukharouba and FE collected and assembled the data; CP and EB performed the H, et al. Time trends of cancer incidence in Setif, Algeria, 1986-2010: an statistical analyses; MHC, SF and DP provided support in the interpretation of observational study. BMC Cancer. 2014;14(637) https://doi.org/10.1186/1471- results; all Authors critically reviewed and approve the manuscript for 2407-14-637. submission. 11. Armitage P, Berry G, Matthews JNS. Statistical methods in medical research. 4th ed. Malden: Blackwell Science; 2002. Ethics approval and consent to participate 12. Kalbfleish J, Prentice R. The statistical analyses of failure time data. 2nd ed. Cancer Registries are identified as collectors of personal data for surveillance New York: Wiley; 2002. purposes without the need of explicit individual consent. The approval of a 13. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. research ethic committee is not required as this descriptive study was GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC conducted without any direct or indirect intervention on patients. CancerBase no. 11. Lyon, France: International Agency for Research on. Nonetheless, The General Director (Dr. Fouad Elissawi) of the Primary Health Cancer. 2013; Available at: http://globocan.iarc.fr Care, MoH, Gaza Strip, has cleared the use of registry data for study purposes 14. Arkoob K, Al-Nsour M, Al-Nemry O, Al-Hajawi B. Epidemiology of breast (letter dated April 8, 2015). cancer in women in Jordan: patient characteristics and survival analysis. East Mediterr Health J. 2010;16:1032–8. Competing interests 15. Seedhom AE, Kamal NN. Factors affecting survival of women diagnosed The authors declare that they have no competing interests. with breast Cancer in El-Minia governorate. Egypt Int J Prev Med. 2011; 2:131–8. 16. Galukande M, Wabinga H, Mirembe F. Breast cancer survival experiences at Publisher’sNote a tertiary hospital in sub-Saharan Africa: a cohort study. World J Surg Oncol. Springer Nature remains neutral with regard to jurisdictional claims in 2015;13:220. https://doi.org/10.1186/s12957-015-0632-4. published maps and institutional affiliations. 17. Smirnov M, Lazarev I, Perry ZH, Ariad S, Kirshtein B. Colorectal cancer in southern Israel: comparison between Bedouin Arab and Jewish patients. Int Author details J Surg. 2016;33(Part A):109–16. Cancer Epidemiology Unit, IRCCS Centro di Riferimento Oncologico, Aviano, Italy. Ministry of Health, PHC, Training and Education Department, Gaza, 18. Allemani C, Sant M, Weir K, Richardson LC, Baili P, Storm H, et al. Breast Palestine. Faculty of Medicine and Cancer Registry, University of Setif, Setif, cancer survival in the US and Europe: a CONCORD high-resolution study. Int Algeria. Centro Nazionale di Epidemiologia, Sorveglianza e Promozione della J Cancer. 2013;132:1170–81. Salute, Istituto Superiore di Sanità, Rome, Italy. Dipartment Morfologia, 19. Minicozzi P, Kaleci S, Maffei S, Allemani C, Giacomin A, Caldarella A, et al. Chirurgia e Medicina Sperimentale, Università di Ferrara - Registro Tumori Disease presentation, treatment and survival for colorectal cancer patients: a Area Vasta Emilia Centrale, Azienda USL Ferrara, - Servizio Prevenzione EUROCARE high-resolution study. Eur J Pub Health. 2013;24:98–100. collettiva e Sanità pubblica, Ferrara, Regione Emilia-Romagna, Italy. WHO 20. Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, Office. Occupied Palestinian Territory, UNDP Building, Elnasr Street, Gaza, et al. Cancer survival in five continents: a worldwide population-based study Palestine. Ministry of Health, Primary Health Care directorate, Gaza, Palestine. (CONCORD). Lancet Oncol. 2008;9:730–56. Panato et al. BMC Cancer (2018) 18:632 Page 10 of 10 21. Sankaranarayanan R, Swaminathan R, Brenner H, Chen K, Chia KS, Chen JG, et al. Cancer survival in Africa, Asia, and central America: a population-based study. Lancet Oncol. 2010;11:165–73. 22. Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel H. Cancer incidence in Egypt: results of the National Population-Based Cancer Registry Program. J Cancer Epidemiol. 2014;2014:1–18. https://doi.org/10.1155/2014/437971 23. Lakkis NA, Adib SM, Osman MH, Musharafieh UM, Hamadeh GN. Breast cancer in Lebanon: incidence and comparison to regional and western countries. Cancer Epidemiol. 2010;34:221–5. 24. WHO. Access to health services for Palestinian people: case studies of five patients in critical conditions who died while waiting to exit the Gaza Strip. West Bank and Gaza: World Health Organization, 2008. Available at: http:// applications.emro.who.int/dsaf/EMROPUB_2008_EN_753.pdf?ua=1. Last access: 16/03/2018. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png BMC Cancer Springer Journals

Survival after the diagnosis of breast or colorectal cancer in the GAZA Strip from 2005 to 2014

Free
10 pages

Loading next page...
 
/lp/springer_journal/survival-after-the-diagnosis-of-breast-or-colorectal-cancer-in-the-dStf6K0Fw0
Publisher
Springer Journals
Copyright
Copyright © 2018 by The Author(s).
Subject
Biomedicine; Cancer Research; Oncology; Surgical Oncology; Health Promotion and Disease Prevention; Biomedicine, general; Medicine/Public Health, general
eISSN
1471-2407
D.O.I.
10.1186/s12885-018-4552-x
Publisher site
See Article on Publisher Site

Abstract

Background: Within a dramatic socio-political context, cancer represents a growing health burden in the Gaza Strip. We investigated the survival experience of people diagnosed with breast (BC) or colorectal (CRC) cancer from 2005 to 2014. Methods: Data included 1360 BC cases (median age 55.1 years) and 722 CRC cases (median age: 59.5 years; 52.5% men) recorded by the Gaza Cancer Registry according to a standard protocol. Clinical information was available for cases diagnosed in 2005–2006 only. Survival probabilities were estimated by Kaplan-Meyer method, while hazard ratios (HRs) and 95% confidence intervals (CI), adjusted for age and sex, were computed to assess factors associated with the risk of death. Results: Five-year survival was 65.1% for women with BC and 50.2% for patients with CRC. Advanced age (> 65 years), stage, and grade increased the death risk. Full access to therapies was associated with a reduced risk of death as compared with patients who had limited access (HR = 0.26, 95% CI:0.13–0.51 for BC; and HR = 0.11, 95% CI: 0.04–0.31 for CRC). Conclusion(s): The 5-year survival after BC or CRC in the Gaza Strip was in line with estimates from surrounding Arab countries, but it was much lower than in developed Mediterranean countries (e.g., in Italy or in Jewish people in Israel). Keywords: Gaza Strip, Cancer survival, Breast cancer, Colorectal cancer Background of death, after cardiovascular diseases, and it accounts The Gaza Strip, a narrow land located in the southern for 20% of the whole expenditure for drugs [5, 6]. part of the Occupied Palestinian Territory (OPT), is an In the OPT, two population-based cancer registries overcrowded area with a population of 1.8 million were established in 1996 by the Palestinian Ministry of people (i.e., 5000 persons per km )[1]. Although most Health (MoH) -one in the West Bank, and one in the of the population in the Gaza Strip has a challengeable Gaza Strip [4]. Given the geopolitical context of the life, with a high rate of poverty - 74% of families were es- Gaza Strip [7, 8], the data collection process cannot fully timated to live below the poverty line [2, 3] - life expect- reflect the whole cancer burden in the area. As a conse- ancy at birth reaches 71.5 years in males and 74.4 years quence, the World Health Organization (WHO) has re- in females [4]. Cancer is the second most common cause cently given support to the Palestinian MoH in improving cancer registration [8]. Of all cases recorded between 2005 and 2014, breast cancer (BC) was the most common cancer among women (26.0% -skin can- * Correspondence: serrainod@cro.it Chiara Panato and Khaled Abusamaan contributed equally to this work. cers included), while colorectal cancer (CRC) was the Cancer Epidemiology Unit, IRCCS Centro di Riferimento Oncologico, Aviano, second most common cancer in men (9.7% of all cases). Italy The Italian MoH promoted the “EUROMED Cancer Friuli Venezia Giulia Cancer Registry, IRCCS Centro di Riferimento Oncologico, Aviano, Italy Network” with the general aim to support extra-European Full list of author information is available at the end of the article © The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. Panato et al. BMC Cancer (2018) 18:632 Page 2 of 10 Union Mediterranean countries in the development of ef- for these cases a multivariate analysis was conducted to fective anti-cancer programs [9, 10]. The ongoing collab- estimate the risk of death. oration with the Gaza Cancer Registry (GCR) was conducted by the National Cancer Institute “Centro di Statistical methods Riferimento Oncologico”, Aviano (notheastern Italy); the The crude survival time was calculated as the time Italian network of cancer registries (AIRTUM); and the elapsed from date of cancer diagnosis to date of death, Italian National Health Institute (ISS), Rome. or to end of follow-up –whichever came first. At univar- Herein, we describe the general characteristics and the iate analysis, the survival time for the totality of BC or crude survival experience of patients diagnosed with BC CRC patients diagnosed from 2005 to 2014 was esti- or with CRC between 2005 and 2014 in the Gaza Strip. mated by means of the Kaplan-Meier method [11]. Furthermore, as selected clinical data were available only For cases diagnosed in 2005–2006 only, a multivariate for cases diagnosed in 2005–2006, we estimated the risks analysis was carried out to statistically assess the role of of death for patients with BC or CRC according to type selected clinical variables on survival. To this end, haz- of therapy, disease, grade, or stage. ard ratios (HRs) for all-cause mortality, and the corre- sponding 95% confidence intervals (95% CIs), were estimated using the Cox proportional hazard model ad- Methods justed for age at diagnosis (< 35, 35–44, 45–54, 55–64, Study population 65–74, 75+ years) and gender, as appropriate [12]. The We described the general characteristics and the cancer proportional hazard assumption was assessed through survival experience of people living in the Gaza Strip, di- Schoenfeld residuals, including interactions with agnosed with BC or CRC in 2005–2014, according to follow-up time [12]. the information recorded in the population-based GCR. Cancer Registries are identified as collectors of personal Results data for surveillance purposes without the need of expli- Breast cancer cit individual consent. The approval of a research ethic The median age of the 1360 women diagnosed with BC committee is not required because neither direct nor in- in the Gaza Strip between 2005 and 2014 was 55.1 years direct intervention on patients took place. Nonetheless, (Inter Quartile Range -IQR: 45.8–64.8 years). The abso- the General Director of the Primary Health Care, MoH, lute number of cases more than doubled, from 178 in (Dr. Fouad Elissawi) cleared the use of the registry data 2005–2006 up to 396 in 2013–2014 (Table 1), with slight for study purposes. The data collection process used by variations in median ages –from 53.0 years (in 2005– GCR is an active one, carried on by GCR trained 2006) to 55.4 years (in 2013–2014). Overall, 76.1% (95% personnel who regularly visit the pathology departments and oncology clinics to collect newly detected cases and Table 1 Description of breast and colorectal cancer incident to update the already recorded ones. The update of the cases diagnosed from 2005 to 2014 in the Gaza Strip vital status is manually checked by means of the death Breast cancer Colorectal cancer registry. Cases Deaths Cases Deaths For the aims of this analysis, to ensure data validity, N = 1360 N = 486 (%) N = 722 N = 361 (%) each case was reviewed by a member of the GCR and Sex co-author of this article (FE). The vital status and – Female 1360 486 (35.7) 343 169 (49.3) eventually – the date of death were ascertained from the Male –– 379 192 (50.7) death registration database at Palestinian MoH. The last follow-up time was December 31st, 2016. Overall, from Age at cancer diagnosis (years) 2005 to 2014, 1495 women were diagnosed with BC (no ≤ 44 331 108 (32.6) 97 33 (32.0) cases of BC were recorded in men during the study 45–54 371 120 (32.4) 163 69 (40.5) period), and 878 people were diagnosed with CRC. This 55–64 319 112 (35.1) 221 114 (49.3) analysis was restricted to 1360 BC and 722 CRC patients ≥ 65 339 146 (43.1) 241 145 (59.3) after exclusion of: cases lacking the full date of birth (7 Calendar year at cancer diagnosis BCs and 21 CRCs); children under 15 years of age (2 BCs and 3 CRCs); and those patients with coincident 2005–2006 178 93 (52.3) 80 58 (72.5) dates of diagnosis and death (126 cases of BC and 132 2007–2008 207 73 (35.3) 124 53 (47.7) cases of CRC). 2009–2010 223 101 (45.3) 136 72 (52.9) Information on therapy, grade, and stage of disease 2011–2012 356 143 (40.2) 165 91 (55.2) was available for cases diagnosed in 2005–2006 only 2013–2014 396 76 (19.2) 217 87 (40.1) (i.e., 178 cases of BC and 80 cases of CRC). Accordingly, Panato et al. BMC Cancer (2018) 18:632 Page 3 of 10 CI: 73.7–78.3) of these women was alive after 3 years, disease were statistically lower than those with a local- 65.1% (95% CI: 62.1–67.4) after 5 years, and 51.9% (95% ized BC stage (p of log-rank test = 0.0314) (Fig. 2b). Con- CI: 47.9–55.7) after 10 years from BC diagnosis (Fig. 1a). cerning HR, advanced stage of disease was associated The probability of survival after BC was strongly influ- with an elevated risk of death as compared with those enced by age, with women aged 65 years or older show- with a localized disease – of borderline statistical signifi- ing the lowest survival rates (i.e., 66.0% after 3, 57.4% cance – (HR = 1.93, 95% CI: 0.98–3.80). Likewise, the after 5, and 45.1% after 10 years from diagnosis) (p < survival probabilities stratified by grade of disease were 0.001) (Fig. 1b). different from each other (p-value = 0.0078) (Fig. 2c), Selected clinical data available for the 178 women with and women diagnosed with poorly or undifferentiated BC diagnosed in 2005–2006 are discussed in detail BC were at 1.67-fold higher risk of death than women (Table 2). The majority of them (60.1%) was diagnosed with well/moderate grade of cancer (HR:1.67, 95% with an advanced stage of disease, but no difference was CI:1.04–2.69) (Table 2). noted between the percentage of women diagnosed with Surgically treated women (87.6%) had the best progno- well or moderately differentiated BC and those diag- sis, and those treated with two or more anti-cancer ther- nosed with a poorly differentiated or undifferentiated apies presented a statistically significant 70% reduction disease. Among these 178 patients with BC, 83.7% in the risk of death, as compared with those who had lit- underwent two or more therapies, in particular surgery tle (i.e., only one type of treatment) or no access (2.9%) (87.6%) and chemotherapy (76,4%). to anti-cancer therapies (Table 2). The 178 women diagnosed with BC between 2005 and 2006 were followed-up to December 31st, 2016 for a Colorectal cancer median period of 63.3 months (IQR: 23.0–100.3 months). The median age of the 722 individuals (47·5% women) During such period, 93 of them (52.2%) died, and 85 diagnosed with CRC in the Gaza Strip between 2005 and were censored. The estimated median survival time was 2014 was 59.5 years (IQR: 51.2–68.6 years), and the ab- 83.7 months (95% CI: 61.3–106.9) (Fig. 2a). Grade and solute number of cases ranged from 80 in 2005–2006 to stage of disease influenced the prognosis. Indeed, the 217 in 2013–2014 (Table 1). The median ages at CRC survival probabilities of women with advanced stage of diagnoses remained stable over time (58.7 years in Fig. 1 Kaplan-Meier estimates of survival probabilities among cases 1360 women diagnosed with breast cancer: overall (a) and according to age class (b). Gaza Strip, 2005–2014 Panato et al. BMC Cancer (2018) 18:632 Page 4 of 10 Table 2 Hazard ratios (HR) of all-cause deaths, with corresponding 95% confidence intervals (CI), among 178 incident breast cancer cases diagnosed in 2005–2006 in the Gaza Strip according to clinical characteristics Cases Deaths (N = 93) N N (%) HR (95% CI) Age at diagnosis (years) < 55 98 47 (48.0) 1 ≥ 55 80 46 (57.5) 1.39 (0.93–2.09) Stage Localized 33 10 (30.3) 1 Regional/Distant 107 57 (53.3) 1.93 (0.98–3.80) Missing 38 26 (68.4) 2.32 (1.10–4.91) Grade Well and Moderately differentiated 75 31 (41.3) 1 Poorly differentiated and Undifferentiated 70 42 (60.0) 1.67 (1.04–2.69) Missing 33 20 (60.6) 1.33 (0.72–2.44) Surgery No 18 14 (77.8) 1 Yes 156 76 (48.7) 0.29 (0.16–0.53) Chemotherapy No 38 23 (60.5) 1 Yes 136 67 (49.3) 0.58 (0.36–0.94) Radiotherapy No 81 46 (56.8) 1 Yes 93 44 (47.3) 0.89 (0·57–1·39) Hormone therapy No 109 63 (57.8) 1 Yes 65 27 (41.5) 0.53 (0.33–0.84) Number of therapies 0–1 25 20 (80.0) 1 2 55 29 (52.7) 0.32 (0.18–0.58) 3 56 23 (41.1) 0.25 (0.13–0.48) 4 38 18 (47.4) 0.26 (0.13–0.51) a b c Estimated using the Cox proportional hazard model adjusted for age; Reference category; The sum does not add up to the total because of missing values 2005–2006, 59.9 years in 2013–2014). Overall, 59.8% As per clinical protocols, 88.8% of these 80 cases diag- (95% CI: 56.0–63.3) of them were alive after 3 years, nosed in 2005–2006 underwent surgery, 87.5% received 50.2% (95% CI: 46.3–54.0) after 5 years, and 40.7% (95% chemotherapy, and only 27.5% radiotherapy. More than CI: 35.6–45.8) after 10 years from diagnosis (Fig. 3a). three quarters of patients underwent two or more thera- The survival probabilities after a CRC diagnosis were peutic regimens (Table 3). not influenced by sex (Fig. 3b). Conversely, survival after Figure 4a shows the overall survival of patients with CRC diagnosis was strongly influenced by age, with pa- CRC diagnoses, the median survival time was tients aged 65 years or older showing the lowest survival 43.3 months (95% CI: 31.4–60.0), and 34 patients were rates (i.e., 49.0% after 3, 40.1% after 5, and 33.8% after censored. Cases with a localized disease had a higher 10 years from diagnosis) (p < 0.001) (Fig. 3c). survival rate (i.e., 61.0% 5-years survival) than those with Women accounted for 60.0% of the 80 patients diag- regional/distant disease (i.e., 27.1% 5-years survival) nosed in 2005–2006 with a CRC (Table 3). Advanced (p-value = 0.0041) (Fig. 4b). Furthermore, CRC patients stage of disease was documented in 49 out of 80 patients with a regional/distant stage of disease had an elevated (61.3%), and a well or moderately differentiated grade of risk of death, as compared to those with a localized dis- cancer was documented in 53 out of 80 patients (66.3%). ease (HR = 3.38, 95% CI: 1.57–7.29) (Table 3). Similarly, Panato et al. BMC Cancer (2018) 18:632 Page 5 of 10 Fig. 2 Kaplan-Meier estimates of survival probabilities among 178 women diagnosed with breast cancer: overall (a); according to stage (b); and grade (c). The Gaza Strip, 2005–2006. The sum does not add up to the total because of missing values survival rates between patients with a well/moderate types of treatments), as compared with those who had grade of CRC (i.e., 53.9% 5-years survival) and those little (i.e., only one type of treatment) or no access (one with a poorly or undifferentiated grade (i.e., 13.6% patient) to anti-cancer therapies (Table 3). 5-years survival) were significantly different (p-value< 0.0001) (Fig. 4c). Likewise, CRC cases diagnosed with Discussion poorly or undifferentiated CRC were at 3.57-fold (95% Female BC and CRC are among the most common can- CI:1.87–6.81) higher risk of death than cases with well/ cers diagnosed every year worldwide in both more- and moderate grade of disease (Table 3). less-developed WHO regions [13]. These cancers are Patients who had been treated with two or more very common also in the Gaza Strip, where the present anti-cancer therapies presented a reduction in the risk of study attempted -for the first time- to estimate the sur- death (HR = 0.36 for those who received 2 out of three vival of people diagnosed with cancer in the Gaza Strip. modalities; HR = 0.11 for cases who underwent all 3 Our findings indicate that 65.1% of women with BC, and Panato et al. BMC Cancer (2018) 18:632 Page 6 of 10 Fig. 3 Kaplan-Meier estimates of survival probabilities among cases 722 cases diagnosed with colorectal cancer: overall (a), according to sex (b) and age class (c). Gaza Strip, 2005–2014 50.2% of patients with CRC were alive after 5 years the luminal B sub-type had a 5-year survival around from diagnosis. In the subgroup of patients with avail- 30%. A possible explanation of these results could be the able clinical information, the majority of patients were small sample size [16]. diagnosed at an advanced stage. Concerning survival after CRC, a study conducted in In agreement with our results, a Jordanian study dis- Israel among Bedouin Arab and Jewish patients with closed a five-year survival for BC patients of 59.3%, CRC is worth mentioning [17]. The five-year overall sur- showing that grade and stage had a significant effect on vival was about 65% in both ethnic groups. However, the survival rates [14]. Mean age at breast cancer diagnosis mean age at diagnosis was lower for the Bedouin Arab was similar in Jordan [14], in Egypt [15], and in the Gaza population (i.e., 57 years) than for the Jewish population Strip. The median survival time after BC in Egypt (i.e., (i.e., 69 years), pointing to a survival disadvantage for 83.8 months) was equal to the estimate in the Gaza Strip the Bedouin Arab ethnic group [17]. The 40% five-year (i.e., 83.7 months) [15] in 2005–2006. Furthermore, in survival for patients living in the Gaza Strip indicated a Uganda 5-year survival probability was between 50 and greater disadvantage in comparison with both Israeli 60% after a BC diagnosis, and in particular women with ethnic groups. Panato et al. BMC Cancer (2018) 18:632 Page 7 of 10 Table 3 Hazard ratios (HR) of all-cause deaths, with corresponding 95% confidence intervals (CI), among 80 cases of colorectal cancers diagnosed in 2005–2006 in the Gaza Strip according to clinical characteristics Cases Deaths (N = 46) N N (%) HR (95% CI) Age at diagnosis (years) < 60 44 23 (52.3) 1 ≥ 60 36 23 (63.9) 1.38 (0.77–2.48) Sex Male 32 20 (62.5) 1 Female 48 26 (54.2) 0.88 (0.48–1.59) Stage Localized 27 10 (37.0) 1 Regional/Distant 49 35 (71.4) 3.38 (1.57–7.29) Grade Well and moderately differentiated 53 23 (43.4) 1 Poorly differentiated and Undifferentiated 22 19 (86.4) 3.57 (1.87–6.81) Surgery No 9 9 (100.0) 1 Yes 71 37 (52.1) 0.27 (0.13–0.62) Chemotherapy No 10 8 (80.0) 1 Yes 70 38 (54.3) 0.37 (0.16–0.87) Radiotherapy No 58 38 (65.5) 1 Yes 22 8 (36.4) 0.24 (0.10–0.56) Number Therapies 0–1 18 16 (88.9) 1 2 40 22 (55.0) 0.36 (0.17–0.74) 3 22 8 (36.4) 0.11 (0.04–0.31) a b c Estimated using Cox proportional hazard model adjust for sex and age; Reference category; The sum does not add up to the total because of missing values The comparison of data from the GCR with those 71.1% in Izmir, Turkey, in women diagnosed from 1995 from highly-developed countries highlighted substantial to 1997 and followed-up to 2003, or to 61.3% in Saudi differences. In the Gaza Strip, the percentage of BC pa- Arabia, among women diagnosed in 1994–1996 and tients with localized disease at diagnosis was about half followed-up to 2001 [21]. Similar variations emerged, at than that recorded in most European countries, and population level for survival after CRC diagnosis, from a similar to the picture described in eastern European raw 5-year survival of nearly 23% in Setif to 52% in Izmir countries [18]. For CRC cases, the proportion of lo- [20]. calized diseases in the Gaza Strip was about two-fold Among the study strengths, the survival of cancer pa- higher than that documented by Italian cancer regis- tients living in the Gaza Strip was assessed at a popula- tries [19]. With respect to treatment, the proportion tion level, while other studies were previously conducted of patients in the Gaza Strip who underwent chemo- in clinical setting [22, 23]; moreover, we described the therapy and/or radiotherapy was higher than the propor- heterogeneity survival. On the other hand, accuracy and tion of Italian patients (88% vs. 39 and 28% vs. 10%, completeness of data collection, in this study, might respectively). have suffered of potential limitations. With regards to In contrast with widely available estimates of cancer the accuracy of information, the data from the GCR may incidence rates, survival estimates at population level in have suffered of limitations due to the socio-economic less developed countries -including the WHO EMR- are situation and to the conflicts in the Gaza Strip, which less common [20]. The 5-year raw survival after BC var- may have limited the activity of the health personnel ied substantially, from 38.8% in Setif (Algeria) [20]to working in the West Bank and in Gaza. Furthermore, Panato et al. BMC Cancer (2018) 18:632 Page 8 of 10 Fig. 4 Kaplan-Meier estimates of survival probabilities among 80 cases diagnosed with colorectal cancer: overall (a); according to stage (b); and grade (c). The Gaza Strip, 2005–2006. The sum does not add up to the total because of missing values because of cultural taboos (e.g., negative and false per- updated indications on the state of oncologic health care ception toward cancer patients with a consequent isola- in the Gaza Strip. Moreover, it tries to address the prob- tion from family members), cancer patients tend to lematic cancer care situation in this population. conceal their disease, which hinders their access to local The closure policy of the Gaza Strip for security rea- hospitals. Concerning completeness, although cancer sons has caused an isolation of Gaza citizens. This isola- registration in the Gaza Strip started in 1996, it still faces tion has affected the possibility to have adequate cancer several obstacles such as lack of appropriate hardware and care for many cancer patients living in the Gaza Strip. In software, insufficient staff, and training of health particular, the denial or delay of permits to travel outside personnel. All these concerns represent key issues in the Gaza Strip for cancer patients referred to its two neigh- accurate assessment of the cancer burden in the Gaza bouring countries (namely, Israel and Egypt) limits the Strip. opportunity of adequate diagnosis and/or treatment. Notwithstanding this lack of completeness, our study Moreover, a number of antineoplastic medications are results represent one of the first attempts to provide denied to patients due to the embargo [5, 24]. Panato et al. BMC Cancer (2018) 18:632 Page 9 of 10 Conclusions Friuli Venezia Giulia Cancer Registry, IRCCS Centro di Riferimento Oncologico, Aviano, Italy. In view of this already acknowledged difficult social, pol- itical, and economical context, the results from the Received: 3 October 2017 Accepted: 24 May 2018 present oncologic investigation further stresses the need to thoroughly re-assess and overcome the obstacles to a proper delivery of health care to the people living in the References Gaza Strip. It is the scope of the continuing collabor- 1. Palestinian Central Bureau of Statistics. Palestine in Figures 2015. Ramallah – Palestine. 2016. http://www.pcbs.gov.ps/Downloads/book2188.pdf (Last ation between Italian cancer registries and the GCR to access: 29 Aug 2017). contribute in supplying updated oncologic data from the 2. Giacaman R, Khatib R, Shabaneh L, Ramlawi A, Sabri B, Sabatinelli G, et al. Gaza Strip. Health status and health services in the occupied Palestinian territory. Lancet. 2009;373:837–49. Abbreviations 3. UNRWA. United Nations Relief and works agency: Gaza in 2020 a liveable BC: Breast cancer; CIs: Confidence intervals; CRC: Colorectal cancer; place? A report by the United Nations country team in the occupied EMR: Eastern Mediterranean region; GCR: Gaza Cancer Registry; HRs: Hazard Palestinian territory, August 2012. United Nations: Jerusalem. 2012. https:// ratios; IQR: Inter Quartile Range; MoH: Ministry of Health; OPT: Occupied www.unrwa.org/newsroom/press-releases/gaza-2020-liveable-place (last Palestinian Territory; WHO: World Health Organization access: 29 Aug 2017). 4. Ministry of Health. Health Status in Palestine-Ministry of Health Annual Acknowledgements report 2014. Palestine. 2015. http://www.moh.gov.ps/portal/Arabic version. The authors wish to thank Mrs. Luigina Mei for editorial assistance. (last access: 29 Aug 2017). 5. Husseini A, Abu-Rmeileh NM, Mikki N, Ramahi TM, Ghosh HA, Barghuthi N, Funding et al. Cardiovascular diseases, diabetes mellitus, and cancer in the occupied This work was supported by the Italian Ministry of Health – project title: Palestinian territory. Lancet. 2009;373:1041–9. “Sorveglianza epidemiologica per il controllo delle malattie neoplastiche nei 6. Ministry of Health. Palestinian Health Information Center (PHIC), Pharmaceutical paesi del Mediterraneo: dalla registrazione del cancro ai modelli statistici” situation in Gaza-2015. Palestine. 2016. http://www.moh.gov.ps/portal/wp- (Grant N.: I85J12000380005). content/uploads/2015 pharmacy (arabic). (Last access: 29 Aug 2017). Role of funding body: The funding body had no direct role in study design 7. American Cancer Society. Global Cancer Facts & Figures 2nd Edition. and data collection, in the data analysis and interpretation, as well as in the Atlanta, USA: American Cancer Society; 2011e. Available at: http:// manuscript writing. oralcancerfoundation.org/wp-content/uploads/2016/03/acspc-027766.pdf. 8. WHO. World Health Organization. occupied Palestinian territory (oPT). Availability of data and materials Situation report # 2, 27 December 2015; http://www.emro.who.int/pse/ The datasets used and/or analysed during the current study are available palestine-infocus/situation-reports.html (Last access: 29 Aug 2017). from the Gaza Cancer Registry (point of contact: MS Haia, 9. Giordano L, Bisanti L, Salamina G, Ancelle Park R, Sancho-Garnier H, haiayaghi@yahoo.com) upon reasonable request. Espinas J, et al. The EUROMED CANCER network: state-of-art of cancer screening programmes in non-EU Mediterranean countries. Eur J Pub Authors’ contributions Health. 2016;26:839. DS conceived and designed the study; CP, DS and KA drafted the article; MD 10. Hamdi Cherif M, Serraino D, Mahnane A, Laouamri S, Zaidi Z, Boukharouba and FE collected and assembled the data; CP and EB performed the H, et al. Time trends of cancer incidence in Setif, Algeria, 1986-2010: an statistical analyses; MHC, SF and DP provided support in the interpretation of observational study. BMC Cancer. 2014;14(637) https://doi.org/10.1186/1471- results; all Authors critically reviewed and approve the manuscript for 2407-14-637. submission. 11. Armitage P, Berry G, Matthews JNS. Statistical methods in medical research. 4th ed. Malden: Blackwell Science; 2002. Ethics approval and consent to participate 12. Kalbfleish J, Prentice R. The statistical analyses of failure time data. 2nd ed. Cancer Registries are identified as collectors of personal data for surveillance New York: Wiley; 2002. purposes without the need of explicit individual consent. The approval of a 13. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. research ethic committee is not required as this descriptive study was GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC conducted without any direct or indirect intervention on patients. CancerBase no. 11. Lyon, France: International Agency for Research on. Nonetheless, The General Director (Dr. Fouad Elissawi) of the Primary Health Cancer. 2013; Available at: http://globocan.iarc.fr Care, MoH, Gaza Strip, has cleared the use of registry data for study purposes 14. Arkoob K, Al-Nsour M, Al-Nemry O, Al-Hajawi B. Epidemiology of breast (letter dated April 8, 2015). cancer in women in Jordan: patient characteristics and survival analysis. East Mediterr Health J. 2010;16:1032–8. Competing interests 15. Seedhom AE, Kamal NN. Factors affecting survival of women diagnosed The authors declare that they have no competing interests. with breast Cancer in El-Minia governorate. Egypt Int J Prev Med. 2011; 2:131–8. 16. Galukande M, Wabinga H, Mirembe F. Breast cancer survival experiences at Publisher’sNote a tertiary hospital in sub-Saharan Africa: a cohort study. World J Surg Oncol. Springer Nature remains neutral with regard to jurisdictional claims in 2015;13:220. https://doi.org/10.1186/s12957-015-0632-4. published maps and institutional affiliations. 17. Smirnov M, Lazarev I, Perry ZH, Ariad S, Kirshtein B. Colorectal cancer in southern Israel: comparison between Bedouin Arab and Jewish patients. Int Author details J Surg. 2016;33(Part A):109–16. Cancer Epidemiology Unit, IRCCS Centro di Riferimento Oncologico, Aviano, Italy. Ministry of Health, PHC, Training and Education Department, Gaza, 18. Allemani C, Sant M, Weir K, Richardson LC, Baili P, Storm H, et al. Breast Palestine. Faculty of Medicine and Cancer Registry, University of Setif, Setif, cancer survival in the US and Europe: a CONCORD high-resolution study. Int Algeria. Centro Nazionale di Epidemiologia, Sorveglianza e Promozione della J Cancer. 2013;132:1170–81. Salute, Istituto Superiore di Sanità, Rome, Italy. Dipartment Morfologia, 19. Minicozzi P, Kaleci S, Maffei S, Allemani C, Giacomin A, Caldarella A, et al. Chirurgia e Medicina Sperimentale, Università di Ferrara - Registro Tumori Disease presentation, treatment and survival for colorectal cancer patients: a Area Vasta Emilia Centrale, Azienda USL Ferrara, - Servizio Prevenzione EUROCARE high-resolution study. Eur J Pub Health. 2013;24:98–100. collettiva e Sanità pubblica, Ferrara, Regione Emilia-Romagna, Italy. WHO 20. Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, Office. Occupied Palestinian Territory, UNDP Building, Elnasr Street, Gaza, et al. Cancer survival in five continents: a worldwide population-based study Palestine. Ministry of Health, Primary Health Care directorate, Gaza, Palestine. (CONCORD). Lancet Oncol. 2008;9:730–56. Panato et al. BMC Cancer (2018) 18:632 Page 10 of 10 21. Sankaranarayanan R, Swaminathan R, Brenner H, Chen K, Chia KS, Chen JG, et al. Cancer survival in Africa, Asia, and central America: a population-based study. Lancet Oncol. 2010;11:165–73. 22. Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel H. Cancer incidence in Egypt: results of the National Population-Based Cancer Registry Program. J Cancer Epidemiol. 2014;2014:1–18. https://doi.org/10.1155/2014/437971 23. Lakkis NA, Adib SM, Osman MH, Musharafieh UM, Hamadeh GN. Breast cancer in Lebanon: incidence and comparison to regional and western countries. Cancer Epidemiol. 2010;34:221–5. 24. WHO. Access to health services for Palestinian people: case studies of five patients in critical conditions who died while waiting to exit the Gaza Strip. West Bank and Gaza: World Health Organization, 2008. Available at: http:// applications.emro.who.int/dsaf/EMROPUB_2008_EN_753.pdf?ua=1. Last access: 16/03/2018.

Journal

BMC CancerSpringer Journals

Published: Jun 4, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off